IL263657B2 - נוגדני אנטי-c5 ושיטות לשימושם - Google Patents

נוגדני אנטי-c5 ושיטות לשימושם

Info

Publication number
IL263657B2
IL263657B2 IL263657A IL26365718A IL263657B2 IL 263657 B2 IL263657 B2 IL 263657B2 IL 263657 A IL263657 A IL 263657A IL 26365718 A IL26365718 A IL 26365718A IL 263657 B2 IL263657 B2 IL 263657B2
Authority
IL
Israel
Prior art keywords
antibody
seq
amino acid
sequence
acid sequence
Prior art date
Application number
IL263657A
Other languages
English (en)
Other versions
IL263657B1 (he
IL263657A (he
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL263657A publication Critical patent/IL263657A/he
Publication of IL263657B1 publication Critical patent/IL263657B1/he
Publication of IL263657B2 publication Critical patent/IL263657B2/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL263657A 2016-06-17 2017-06-16 נוגדני אנטי-c5 ושיטות לשימושם IL263657B2 (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016120325 2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en) 2016-06-17 2017-06-16 Anti-c5 antibodies and methods of use

Publications (3)

Publication Number Publication Date
IL263657A IL263657A (he) 2019-01-31
IL263657B1 IL263657B1 (he) 2025-08-01
IL263657B2 true IL263657B2 (he) 2025-12-01

Family

ID=59969459

Family Applications (2)

Application Number Title Priority Date Filing Date
IL263657A IL263657B2 (he) 2016-06-17 2017-06-16 נוגדני אנטי-c5 ושיטות לשימושם
IL300611A IL300611A (he) 2016-06-17 2017-06-16 נוגדני אנטי–c5 ושיטות לשימושם

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL300611A IL300611A (he) 2016-06-17 2017-06-16 נוגדני אנטי–c5 ושיטות לשימושם

Country Status (19)

Country Link
EP (1) EP3472316A4 (he)
JP (4) JP6202774B1 (he)
KR (2) KR102226975B1 (he)
CN (3) CN109312326B (he)
AU (1) AU2017285763B2 (he)
BR (1) BR112018075688A2 (he)
CA (1) CA3021956A1 (he)
CL (1) CL2018003573A1 (he)
CR (1) CR20190013A (he)
EA (1) EA201990018A1 (he)
IL (2) IL263657B2 (he)
MX (2) MX2018015030A (he)
MY (1) MY187848A (he)
PE (2) PE20240825A1 (he)
PH (1) PH12018502354B1 (he)
SG (2) SG11201705584VA (he)
TW (5) TW202337903A (he)
UA (1) UA126561C2 (he)
WO (1) WO2017217524A1 (he)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
EP4600372A3 (en) 2014-12-19 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG10202012243VA (en) 2016-06-14 2021-01-28 Regeneron Pharma Anti-c5 antibodies and uses thereof
IL263657B2 (he) * 2016-06-17 2025-12-01 Chugai Pharmaceutical Co Ltd נוגדני אנטי-c5 ושיטות לשימושם
KR102102734B1 (ko) 2016-08-05 2020-04-22 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
JP2020536097A (ja) * 2017-10-04 2020-12-10 アレクシオン ファーマシューティカルズ， インコーポレイテッド 膜性増殖性糸球体腎炎患者の処置のための抗ｃ５抗体の投薬量および投与
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
JP7653909B2 (ja) 2018-09-06 2025-03-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ヒト化抗ｃ５抗体とその利用
EP3958901A4 (en) * 2019-04-24 2023-07-19 The Trustees of the University of Pennsylvania BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
KR20230038773A (ko) * 2020-07-15 2023-03-21 바이오션, 인코포레이티드 C5에 결합하는 항체 및 이의 용도
CN117042798A (zh) * 2020-12-25 2023-11-10 宾夕法尼亚大学理事会 人源化抗-c5抗体和因子h融合蛋白及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029697A1 (en) * 1994-05-02 1995-11-09 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
WO2010015608A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
US20110111406A1 (en) * 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2014160958A1 (en) * 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
WO2015134894A1 (en) * 2014-03-07 2015-09-11 Alexion Pharmaceuticals, Inc. Anti-c5 antibodies having improved pharmacokinetics
US20160068592A1 (en) * 2013-01-31 2016-03-10 Seoul National University R&Db Foundation C5 antibody and method for preventing and treating complement-related diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0230985Y2 (he) 1985-07-08 1990-08-21
JP4643139B2 (ja) 2001-06-12 2011-03-02 テレフオンアクチーボラゲット エル エム エリクソン（パブル） Ｕｍｔｓ地上無線アクセスネットワーク（ｕｔｒａｎ）での同期
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
JP4333939B2 (ja) 2001-08-27 2009-09-16 ロード・コーポレーション トロリ線の吊架装置
DE10253331A1 (de) 2002-11-14 2004-06-03 Symrise Gmbh & Co. Kg Verwendung von trans-Pellitori als Aromastoff
US7267849B2 (en) 2004-03-02 2007-09-11 Nitto Denko Corporation Compensator for liquid crystal display
KR20080069889A (ko) 2007-03-20 2008-07-29 (주)화도 폴리에틸렌 관
EP2129681A2 (en) * 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
JP5336846B2 (ja) 2007-04-11 2013-11-06 積水化学工業株式会社 架橋ポリビニルアセタール樹脂の製造方法及び架橋ポリビニルアセタール樹脂
KR20100054403A (ko) 2008-11-14 2010-05-25 삼성전자주식회사 온라인 공동 작문 장치 및 방법
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
KR20110111007A (ko) 2010-04-02 2011-10-10 이화여자대학교 산학협력단 Ｌ／ｄ 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체
KR20110122011A (ko) 2010-05-03 2011-11-09 황보철종 매장 포인트 통합 관리 시스템 및 그 방법
WO2014028354A1 (en) * 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
BR112017011235A2 (pt) * 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
CR20180364A (es) * 2015-12-18 2018-08-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos de uso
IL263657B2 (he) * 2016-06-17 2025-12-01 Chugai Pharmaceutical Co Ltd נוגדני אנטי-c5 ושיטות לשימושם

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029697A1 (en) * 1994-05-02 1995-11-09 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
US20110111406A1 (en) * 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010015608A1 (en) * 2008-08-05 2010-02-11 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
US20160068592A1 (en) * 2013-01-31 2016-03-10 Seoul National University R&Db Foundation C5 antibody and method for preventing and treating complement-related diseases
WO2014160958A1 (en) * 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
WO2015134894A1 (en) * 2014-03-07 2015-09-11 Alexion Pharmaceuticals, Inc. Anti-c5 antibodies having improved pharmacokinetics

Also Published As

Publication number Publication date
IL263657B1 (he) 2025-08-01
RU2019100222A3 (he) 2020-11-05
JP2022091748A (ja) 2022-06-21
TWI610941B (zh) 2018-01-11
SG11201705584VA (en) 2018-05-30
WO2017217524A1 (en) 2017-12-21
TWI789369B (zh) 2023-01-11
TW201809000A (zh) 2018-03-16
UA126561C2 (uk) 2022-11-02
KR102226975B1 (ko) 2021-03-11
EP3472316A1 (en) 2019-04-24
TW202532438A (zh) 2025-08-16
JP2024102181A (ja) 2024-07-30
TWI807666B (zh) 2023-07-01
CN115925922A (zh) 2023-04-07
PE20190394A1 (es) 2019-03-13
CA3021956A1 (en) 2017-12-21
MX2018015030A (es) 2019-04-22
CR20190013A (es) 2019-03-05
IL263657A (he) 2019-01-31
MX2023001360A (es) 2023-02-27
NZ748003A (en) 2024-12-20
KR101852739B1 (ko) 2018-04-30
EA201990018A1 (ru) 2019-08-30
CL2018003573A1 (es) 2019-02-01
TW202337903A (zh) 2023-10-01
PE20240825A1 (es) 2024-04-18
JP6202774B1 (ja) 2017-09-27
EP3472316A4 (en) 2020-01-08
PH12018502354B1 (en) 2024-02-23
CN115960223A (zh) 2023-04-14
TW201808996A (zh) 2018-03-16
JP2018009021A (ja) 2018-01-18
JP7032077B2 (ja) 2022-03-08
RU2019100222A (ru) 2020-07-17
KR20190009273A (ko) 2019-01-28
PH12018502354A1 (en) 2019-09-23
CN109312326A (zh) 2019-02-05
AU2017285763A1 (en) 2018-11-08
JP2017226655A (ja) 2017-12-28
AU2017285763B2 (en) 2024-02-01
BR112018075688A2 (pt) 2019-04-02
MY187848A (en) 2021-10-26
IL300611A (he) 2023-04-01
SG10201800265UA (en) 2018-02-27
TW202239766A (zh) 2022-10-16
CN109312326B (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
US20240052021A1 (en) Anti-c5 antibodies and methods of use
CA3005592C (en) Anti-c5 antibodies and methods of use
KR102226975B1 (ko) 항-c5 항체 및 사용 방법
HK40085591A (en) Anti-c5 antibodies and methods of use
HK40084339A (en) Anti-c5 antibodies and methods of use
EA041632B1 (ru) Антитела к с5 и способы их применения
HK1251942B (zh) 抗-c5抗体及使用方法